Ratliff John D 4
4 · LABORATORY CORP OF AMERICA HOLDINGS · Filed Feb 13, 2019
Insider Transaction Report
Form 4
Ratliff John D
CEO, Covance Drug Development
Transactions
- Exercise/Conversion
Common Stock
2019-02-11+6,100→ 16,765 total - Tax Payment
Common Stock
2019-02-11$144.29/sh−1,973$284,684→ 14,792 total - Exercise/Conversion
Restricted Stock Unit
2019-02-11−6,100→ 18,374 total→ Common Stock (6,100 underlying)
Holdings
- 40(indirect: By Trust)
Common Stock
- 80(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- [F2]Stock withholding to satisfy tax withholding obligations.
- [F3]The reporting person is not a trustee of the irrevocable trust and disclaims beneficial ownership of the shares.
- [F4]The Restricted Stock Units vested in three equal annual installments beginning on 2/9/17 and are now fully vested.
- [F5]This number reflects the aggregate number of Restricted Stock Units held by the reporting person.